AstraZeneca settles FCPA case with SEC for $5.5M

Biopharmaceutical-company AstraZeneca has reached a $5.5 million settlement with the SEC to settle claims that it violated the Foreign Corrupt Practices Act by making improper payments to state-controlled healthcare providers in China and Russia. Jaclyn Jaeger reports.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.